{"protocolSection": {"identificationModule": {"nctId": "NCT00379288", "orgStudyIdInfo": {"id": "P04139"}, "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)", "officialTitle": "A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-09-19", "studyFirstSubmitQcDate": "2006-09-19", "studyFirstPostDateStruct": {"date": "2006-09-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-07-15", "resultsFirstSubmitQcDate": "2010-07-15", "resultsFirstPostDateStruct": {"date": "2010-08-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol combination (F/SC) (250/50 mcg BID and 500/50 mcg BID) in subjects with persistent asthma who require maintenance treatment on inhaled glucocorticosteroids (ICS); evaluator-blind.\n\nIn addition, the extrapulmonary effects on 24-hour plasma cortisol area under curve (AUC), of MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, F/SC MDI 250/50 mcg BID, and F/SC MDI 500/50 mcg BID will be evaluated."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 404, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MF/F 200/10 mcg BID", "type": "EXPERIMENTAL", "interventionNames": ["Drug: mometasone furoate combination MDI 200/10 mcg BID"]}, {"label": "MF/F 400/10 mcg BID", "type": "EXPERIMENTAL", "interventionNames": ["Drug: mometasone furoate combination MDI 400/10 mcg BID"]}, {"label": "F/SC 250/50 mcg BID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Fluticasone/Salmeterol 250/50 mcg BID"]}, {"label": "F/SC 500/50 mcg BID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Fluticasone/Salmeterol 500/50 mcg BID"]}], "interventions": [{"type": "DRUG", "name": "mometasone furoate combination MDI 200/10 mcg BID", "description": "MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year", "armGroupLabels": ["MF/F 200/10 mcg BID"], "otherNames": ["SCH 418131"]}, {"type": "DRUG", "name": "mometasone furoate combination MDI 400/10 mcg BID", "description": "MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year", "armGroupLabels": ["MF/F 400/10 mcg BID"], "otherNames": ["SCH 418131"]}, {"type": "DRUG", "name": "Fluticasone/Salmeterol 250/50 mcg BID", "description": "F/SC 250/50 twice daily for 1 year", "armGroupLabels": ["F/SC 250/50 mcg BID"], "otherNames": ["Seretide"]}, {"type": "DRUG", "name": "Fluticasone/Salmeterol 500/50 mcg BID", "description": "F/SC 500/50 twice daily for 1 year", "armGroupLabels": ["F/SC 500/50 mcg BID"], "otherNames": ["Seretide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Number of All Randomized Subjects Reporting Adverse Events (AEs).", "description": "AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months.\n* Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist \\[LABA\\]) for at least 12 weeks prior to Screening and have been on a stable regimen for at least 2 weeks prior to Screening.\n\n  * Medium daily doses of ICS:\n\n    * \\> 500 to 1000 mcg beclomethasone chlorofluorocarbon (CFC)\n    * \\> 250 to 500 mcg beclomethasone hydrofluoroalkane (HFA)\n    * \\> 600 to 1000 mcg budesonide dry powder inhaler (DPI)\n    * \\> 1000 to 2000 mcg flunisolide\n    * \\> 250 to 500 mcg fluticasone\n    * 400 mcg MF\n    * \\> 1000 to 2000 mcg triamcinolone acetonide\n  * High daily doses of ICS:\n\n    * \\> 1000 mcg beclomethasone CFC\n    * \\> 500 mcg beclomethasone HFA\n    * \\> 1000 mcg budesonide DPI\n    * \\> 2000 mcg flunisolide\n    * \\> 500 mcg fluticasone\n    * \\> 400 mcg MF\n    * \\> 2000 mcg triamcinolone acetonide\n* If there is no inherent harm in changing the subject's current asthma therapy, the subject must discontinue prescribed ICS or ICS/LABA combination at Baseline.\n* Must show evidence of reversibility within the last 12 months or during the Screening Period. Historical reversibility defined as an increase in absolute forced expiratory volume in 1 second (FEV1) of \\>= 12% and \\>= 200 mL will qualify if performed within 12 months of Screening. If no historical reversibility, subject must demonstrate an absolute FEV1 of \\>= 12% and \\>= 200 mL within 10 to 15 minutes after four puffs of salbutamol at Visit 1 or anytime prior to Baseline.\n* At Screening and Baseline, FEV1 must be \\>= 50% predicted, when restricted medications are withheld for the appropriate intervals.\n* Complete blood count, blood chemistries, urinalysis, and electrocardiogram (ECG) conducted at Screening must be within normal limits or clinically acceptable to the investigator/sponsor. A chest x-ray performed at Screening or within 12 months prior must be clinically acceptable.\n* A female of childbearing potential must be using a medically acceptable, adequate form of birth control:\n\n  * prescribed hormonal contraceptives;\n  * medically prescribed intrauterine device (IUD);\n  * medically prescribed transdermal contraceptive;\n  * condom in combination with spermicide;\n  * monogamous relationship with a male partner who has had a vasectomy.\n\nBirth control must have started at least 3 months prior to Screening. Subject must agree to continue its use for the duration of the study. A subject of childbearing potential who is not currently sexually active must agree to use a medically acceptable method should she become sexually active during the study. Women who have been surgically sterilized or are at least 1 year postmenopausal are not considered to be of childbearing potential. A subject of childbearing potential must have a negative serum pregnancy test at Screening.\n\nKey Exclusion Criteria:\n\n* A change (increase or decrease) in absolute FEV1 of \\> 20% at any time from the Screening Visit up to, and including, the Baseline Visit.\n* A subject who requires the use of \\> 12 inhalations per day of short-acting beta-agonist (SABA) MDI or \\> 2 nebulized treatments per day of 2.5 mg salbutamol, on any 2 consecutive days from the Screening Visit up to, and including, the Baseline Visit.\n* A subject who experiences a clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication \\[other than SABA\\]) at any time from the Screening Visit up to, and including, the Baseline Visit.\n* A subject who has ever required ventilator support for respiratory failure secondary to asthma.\n* A subject who is a smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history \\> 10 pack-years.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "20874458", "type": "RESULT", "citation": "Maspero JF, Nolte H, Cherrez-Ojeda I; P04139 Study Group. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma. 2010 Dec;47(10):1106-15. doi: 10.3109/02770903.2010.514634. Epub 2010 Nov 1. Erratum In: J Asthma. 2011 Feb;48(1):114."}, {"pmid": "25044280", "type": "DERIVED", "citation": "Maspero J, Cherrez I, Doherty DE, Tashkin DP, Kuna P, Kuo WL, Gates D, Nolte H, Chylack LT Jr. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Respir Med. 2014 Sep;108(9):1355-62. doi: 10.1016/j.rmed.2014.04.015. Epub 2014 May 2."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects starting study are those subjects who completed screening procedures and randomized.", "groups": [{"id": "FG000", "title": "MF/F 200/10 mcg BID", "description": "mometasone furoate/formoterol (MF/F) 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "FG001", "title": "MF/F 400/10 mcg BID", "description": "MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "FG002", "title": "F/SC 250/50 mcg BID", "description": "fluticasone/salmeterol combination (F/SC) 250/50 twice daily for 1 year"}, {"id": "FG003", "title": "F/SC 500/50 mcg BID", "description": "F/SC 500/50 twice daily for 1 year"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "141"}, {"groupId": "FG001", "numSubjects": "130"}, {"groupId": "FG002", "numSubjects": "68"}, {"groupId": "FG003", "numSubjects": "65"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "108"}, {"groupId": "FG002", "numSubjects": "58"}, {"groupId": "FG003", "numSubjects": "57"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Treatment Failure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Subject withdrew-unrelated to study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Subject withdrew-related to study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Noncompliance with protocol", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Did not meet protocol eligibility", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Administrative", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MF/F 200/10 mcg BID", "description": "MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "BG001", "title": "MF/F 400/10 mcg BID", "description": "MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "BG002", "title": "F/SC 250/50 mcg BID", "description": "F/SC 250/50 twice daily for 1 year"}, {"id": "BG003", "title": "F/SC 500/50 mcg BID", "description": "F/SC 500/50 twice daily for 1 year"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "68"}, {"groupId": "BG003", "value": "65"}, {"groupId": "BG004", "value": "404"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.7", "spread": "15.2"}, {"groupId": "BG001", "value": "39.3", "spread": "14.5"}, {"groupId": "BG002", "value": "32.4", "spread": "14.9"}, {"groupId": "BG003", "value": "37.1", "spread": "15.0"}, {"groupId": "BG004", "value": "35.5", "spread": "15.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "40"}, {"groupId": "BG004", "value": "256"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "25"}, {"groupId": "BG004", "value": "148"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Number of All Randomized Subjects Reporting Adverse Events (AEs).", "description": "AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "1 year", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg BID", "description": "MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "OG001", "title": "MF/F 400/10 mcg BID", "description": "MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year"}, {"id": "OG002", "title": "F/SC 250/50 mcg BID", "description": "F/SC 250/50 twice daily for 1 year"}, {"id": "OG003", "title": "F/SC 500/50 mcg BID", "description": "F/SC 500/50 twice daily for 1 year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "130"}, {"groupId": "OG002", "value": "68"}, {"groupId": "OG003", "value": "65"}]}], "classes": [{"title": "Treatment-Emergent Adverse Events (TEAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "50"}]}]}, {"title": "Related Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "13"}]}]}, {"title": "Severe Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "4"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with TEAEs", "paramValue": "77.4", "ciPctValue": "95"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with related AEs", "paramValue": "28.4", "ciPctValue": "95"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with severe AEs", "paramValue": "5.7", "ciPctValue": "95"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with serious AEs", "paramValue": "4.9", "ciPctValue": "95"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with TEAEs", "paramValue": "79.2", "ciPctValue": "95"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with related AEs", "paramValue": "23.1", "ciPctValue": "95"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with severe AEs", "paramValue": "3.8", "ciPctValue": "95"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with serious AEs", "paramValue": "6.1", "ciPctValue": "95"}, {"groupIds": ["OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with TEAEs", "paramValue": "82.4", "ciPctValue": "95"}, {"groupIds": ["OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with related AEs", "paramValue": "23.5", "ciPctValue": "95"}, {"groupIds": ["OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with severe AEs", "paramValue": "5.9", "ciPctValue": "95"}, {"groupIds": ["OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with serious AEs", "paramValue": "5.8", "ciPctValue": "95"}, {"groupIds": ["OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with TEAEs", "paramValue": "76.9", "ciPctValue": "95"}, {"groupIds": ["OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with related AEs", "paramValue": "20", "ciPctValue": "95"}, {"groupIds": ["OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with severe AEs", "paramValue": "6.2", "ciPctValue": "95"}, {"groupIds": ["OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "percentage of subjects with serious AEs", "paramValue": "3.1", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "MF/F MDI 200/10 mcg BID", "description": "MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year", "seriousNumAffected": 7, "seriousNumAtRisk": 141, "otherNumAffected": 93, "otherNumAtRisk": 141}, {"id": "EG001", "title": "MF/F MDI 400/10 mcg BID", "description": "MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year", "seriousNumAffected": 8, "seriousNumAtRisk": 130, "otherNumAffected": 82, "otherNumAtRisk": 130}, {"id": "EG002", "title": "F/SC MDI 250/50 mcg BID", "description": "F/SC 250/50 twice daily for 1 year", "seriousNumAffected": 4, "seriousNumAtRisk": 68, "otherNumAffected": 51, "otherNumAtRisk": 68}, {"id": "EG003", "title": "F/SC MDI 500/50 mcg BID", "description": "F/SC 500/50 twice daily for 1 year", "seriousNumAffected": 2, "seriousNumAtRisk": 65, "otherNumAffected": 41, "otherNumAtRisk": 65}], "seriousEvents": [{"term": "IDIOPATHIC THROMBOCYTOPENIC PURPURA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "LENS DISORDER", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "OCULAR HYPERTENSION", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "VISUAL ACUITY REDUCED", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ASCITES", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "DIVERTICULUM INTESTINAL HAEMORRHAGIC", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ELECTROCUTION", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "BILIARY COLIC", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "HEAD INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ROAD TRAFFIC ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "VERTEBRAL INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "GASTRIC CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "METASTATIC NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "DEPRESSED LEVEL OF CONSCIOUSNESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ABORTION SPONTANEOUS", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}], "otherEvents": [{"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 6, "numAffected": 5, "numAtRisk": 65}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 8, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}]}, {"term": "APHTHOUS STOMATITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "PYREXIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 65}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 17, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 29, "numAffected": 20, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 17, "numAffected": 14, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 65}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 14, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 16, "numAffected": 13, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 13, "numAffected": 9, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 13, "numAffected": 11, "numAtRisk": 65}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 39, "numAffected": 29, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 34, "numAffected": 21, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 19, "numAffected": 13, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 9, "numAffected": 8, "numAtRisk": 65}]}, {"term": "PHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 15, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 12, "numAffected": 9, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 65}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 9, "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 10, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 11, "numAffected": 7, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}]}, {"term": "MUSCLE SPASMS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 8, "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 6, "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 7, "numAffected": 4, "numAtRisk": 65}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 77, "numAffected": 33, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 85, "numAffected": 31, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 47, "numAffected": 17, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 31, "numAffected": 13, "numAtRisk": 65}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 5, "numAffected": 2, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}]}, {"term": "DYSPHONIA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 9, "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}]}, {"term": "PHARYNGOLARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 11, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "RHINITIS ALLERGIC", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 11, "numAtRisk": 141}, {"groupId": "EG001", "numEvents": 18, "numAffected": 9, "numAtRisk": 130}, {"groupId": "EG002", "numEvents": 11, "numAffected": 6, "numAtRisk": 68}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 65}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Chile", "Ecuador", "Guatemala", "Mexico", "Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Blood culture", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}